Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints | Zendy

Maiken Cavling Arendrup | Zendy; Michael A. Pfaller | Zendy

Open Access

Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints

Author(s) -

Maiken Cavling Arendrup,

Michael A. Pfaller

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00355-12

Subject(s) - caspofungin , etest , candida krusei , microbiology and biotechnology , candida glabrata , biology , breakpoint , antifungal , fluconazole , antibiotics , genetics , gene , chromosomal translocation

The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed forCandida krusei (73.1%) andCandida glabrata (33.1%). The revised breakpoints cannot be safely adopted for these two species.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research